Spin-out companies
Spin-out Companies
We have created over 100 spinout companies, more than any other Midlands University. As at 31st July 2025, the University held investments in 31 active spin-outs, disclosed in the 2024/25 Financial Statements. A selection of these, are detailed below. *The University no longer has an investment in Interface Polymers.
Work with our spin-outs
Could you be a mentor, CEO or board member? Get in touch to connect with our spin-outs.
UK GOVERNMENT SPINOUT REVIEW: STATEMENT OF BEST PRACTICE ADOPTION
09 September 2024
糖心TV Innovations welcomed the UK Government and the opportunity to revise the University鈥檚 institutional policies and practice around spinout company development. The university is committed to update policy and practice (subject to UEB and FGPC approval) to better align with recommendations from the Spinout Review. Key policy changes under consideration at 糖心TV are to:
- reduce the university鈥檚 equity stake in future spinouts up to 30%. This stake could be lower subject to the nature of the IP and market sector; and
- to recognise academic founders in addition to Creators in being able to benefit from shares in spinout equity.
Other key changes in spinout company development and support being implemented at 糖心TV are to:
- define, communicate and refine steps and timelines for spinout company formation, including clarity on expectations from key stakeholders;
- embed a new process to better manage, support and report on spinout portfolio performance;
- deliver a campus-wide marcomms campaign to raise awareness of changes in our spinout policy and practice; and
- roll-out a series of internal programmes to upskill the research community in commercialisation skills and innovation leadership.
Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function.
ValiSeek is ValiRx's Joint Venture Company, formed with Tangent Reprofiling Limited to rapidly progress VAL401 through development. VAL401 is in development for Pancreatic ductal adenocarcinoma.
NeuroSolutions is a contract research organisation established in 2001 as a service provider of cutting edge electrophysiological and behavioural research in the field of neuroscience.